A Prospective Randomized Evaluation of Topical Gatifloxacin on Conjunctival Flora in Patients Undergoing Intravitreal Injections

Ophthalmology

Volumn 116, Issue 8, 2009, Pages 1498-1501

  Moss, Jason M ^a   Sanislo, Steven R ^a   Ta, Christopher N ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GATIFLOXACIN; POVIDONE IODINE;

ADULT; AGED; ARTICLE; BACTERIAL FLORA; BACTERIAL GROWTH; BACTERIUM CULTURE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELF ADMINISTRATION; ENDOPHTHALMITIS; EYE; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; INCIDENCE; INFECTION PREVENTION; INJECTION SITE; INSTRUMENTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEEDLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SINGLE BLIND PROCEDURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BACTERIA; COLONY COUNT, MICROBIAL; CONJUNCTIVA; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; POVIDONE-IODINE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; VITREOUS BODY;

EID: 67949109540     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.02.024     Document Type: Article

References (23)

1. Ohm J. Über die Behandlung der Netzhautablösung durch operative Entleerung der subretinalen Flüssigkeit und Einspritzung von Luft in den Glaskörper. Albrecht von Graefes Arch Ophthalmol 79 (1911) 442-450
2. Rycroft B.W. Penicillin and the control of deep intra-ocular infection. Br J Ophthalmol 29 (1945) 57-87
3. Schneider J., and Frankel S.S. Treatment of late postoperative intraocular infections with intraocular injection of penicillin. Arch Ophthalmol 37 (1947) 304-307
4. Henry K., Cantrill H., Fletcher C., et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 103 (1987) 17-23
5. Antcliff R.J., Spalton D.J., Stanford M.R., et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108 (2001) 765-772
6. Greenberg P.B., Martidis A., Rogers A.H., et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion [letter]. Br J Ophthalmol 86 (2002) 247-248
7. Martidis A., Duker J.S., and Puliafito C.A. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 119 (2001) 1380-1383
8. Scott I.U., Flynn Jr. H.W., and Rosenfeld P.J. Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am J Ophthalmol 136 (2003) 737-739
9. Young S., Larkin G., Branley M., and Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 29 (2001) 2-6
10. Jorge R., Costa R.A., Calucci D., et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina 26 (2006) 1006-1013
11. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
12. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
13. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
14. Yoganathan P., Deramo V.A., Lai J.C., et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26 (2006) 994-998
15. Jager R.D., Aiello L.P., Patel S.C., and Cunningham Jr. E.T. Risks of intravitreous injection: a comprehensive review. Retina 24 (2004) 676-698
16. Scott I.U., and Flynn Jr. H.W. The role of topical antibiotic prophylaxis for intravitreal injections. Arch Ophthalmol 125 (2007) 974-976
17. Ta C.N. Topical antibiotic prophylaxis in intraocular injections. Arch Ophthalmol 125 (2007) 972-974
18. Scott I.U., and Flynn Jr. H.W. Reducing the risk of endophthalmitis following intravitreal injections. Retina 27 (2007) 10-12
19. Ta C.N., Egbert P.R., Singh K., et al. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology 109 (2002) 2036-2040
20. de Caro J.J., Ta C.N., Ho H.K., et al. Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. Retina 28 (2008) 877-883
21. Levine C., Hiasa H., and Marians K.J. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochem Biophys Acta 1400 (1998) 29-43
22. Rodeheaver G., Bellamy W., Kody M., et al. Bactericidal activity and toxicity of iodine-containing solutions in wounds. Arch Surg 117 (1982) 181-186
23. Grimes S.R., Mein C.E., and Trevino S. Preoperative antibiotic and povidone-iodine preparation of the eye. Ann Ophthalmol 23 (1991) 263-266